| |
Best Response in 6 months
| | | | | |
|---|
| |
CR/PR (n = 71)
|
SD/PD (n = 185)
|
Univariate
|
Multivariate1
|
Multivariate2
|
|---|
| |
N (%)
|
N (%)
|
Relative Risk (95% CI)
|
Relative Risk (95% CI)
|
P-value
|
Relative Risk (95% CI)
|
P-value
|
|---|
|
Antibiotic Use
|
|
ATB-
|
59 (28.1)
|
151 (71.9)
|
1.00
|
1.00
| |
1.00
| |
|
ATB +
|
12 (26.1)
|
34 (73.9)
|
1.03 (0.85–1.24)
|
1.04 (0.88–1.24)
|
0.633
|
1.08 (0.93–1.26)
|
0.321
|
|
PPI Use
|
|
No
|
50 (25.6)
|
145 (74.4)
|
1.00
|
1.00
| |
1.00
| |
|
Yes
|
21 (34.4)
|
40 (65.6)
|
1.00 (0.82–1.22)
|
1.00 (0.83–1.21)
|
1.000
|
1.00 (0.82–1.21)
|
1.000
|
|
Prior Chemotherapy
|
|
No
|
41 (37.3)
|
69 (62.7)
|
1.00
|
1.00
| |
1.00
| |
|
Yes
|
30 (20.5)
|
116 (79.5)
|
1.27 (1.07–1.50)
|
1.26 (1.07–1.48)
|
0.007*
|
1.24 (1.05–1.47)
|
0.013*
|
|
Age (binary)
|
|
< = 67
|
39 (27.5)
|
103 (72.5)
|
1.00
|
NA
|
NA
|
1.00
| |
|
> 67
|
32 (28.1)
|
82 (71.9)
|
1.00 (0.86, 1.17)
|
NA
|
NA
|
1.00 (0.87–1.15)
|
1.000
|
|
ECOG Performance Status
|
|
0
|
18 (31.6)
|
39 (68.4)
|
1.00
|
NA
|
NA
|
1.00
| |
|
1/2
|
53 (26.8)
|
145 (73.2)
|
1.07 (0.88–1.30)
|
NA
|
NA
|
1.06 (0.89–1.26)
|
0.530
|
|
Targeted Therapy
|
|
No
|
64 (29.8)
|
151 (70.2)
|
1.00
|
NA
|
NA
|
1.00
| |
|
Yes
|
7 (17.1)
|
34 (82.9)
|
1.18 (1.00–1.39)
|
NA
|
NA
|
1.11 (0.95–1.29)
|
0.188
|
- *Statistically Significant, when p < 0.05; 1: Adjusted for significant risk factors in Table 1/adjusted for PPI and Chemotherapy; 2: Adjusted for PPI, Chemotherapy, Age (cut at the median age of 67), ECOG (0 vs. combined 1/2), and Targeted Therapy; *Negative response ( SD&PD) is considered as event/1. Positive response (CR&PR) is considered as reference/0. CR complete response, PP Proton pump inhibitor, PR partial response, PD progressive disease, SD Stable disease
